US58933Y1055
© BusinessWire
01.10.2024
MRK
LISTED
NYSE
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases.
“By actively depleting B-cells, CN201 offers applications spanning bot...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
MRK
LISTED
NYSE
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, October 31. During the call, company executives will provide an overview of Merck’s performance for the quarter.
Investors, journalists...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
MRK
LISTED
NYSE
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data highlighting the long-term efficacy and safety of tulisokibart (MK-7240), an investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in ulcerative colitis (UC) and Crohn’s dis...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
25.09.2024
MRK
LISTED
NYSE
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYFORM-007 trial evaluating the investigational fixed-dose combination of favezelimab, Merck’s anti-LAG-3 antibody, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, did not meet its primary endpoint of overall survival (OS) for the t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
25.09.2024
MRK
LISTED
NYSE
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved new indications for KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in certain lung and urothelial cancers:
KEYTRUDA in combination with chemotherapy as a neoadjuvant treatment,...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
MRK
LISTED
NYSE
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
News Preview
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly USDA-approved NOBIVAC® NXT vaccine platform to include a best in class solution to protect cats against one of the most common feline infectious disea...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2024
MRK
LISTED
NYSE
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for two indications in gynecologic cancers. The first opinion re...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
MRK
LISTED
NYSE
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural me...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2024
MRK
LISTED
NYSE
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first-time presentation of overall survival (OS) results from the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2024
MRK
LISTED
NYSE
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYNOTE-006 trial, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma. Based on 10 years of follow-up, the data showed sustained improved survival ou...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2024
MRK
LISTED
NYSE
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Ei...
Themefolio
Profiler
Peergroup
© BusinessWire
14.09.2024
MRK
LISTED
NYSE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of overall survival (OS) results from the pivotal Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with concurrent chemoradiotherapy (CRT) fo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
14.09.2024
MRK
LISTED
NYSE
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced overall survival (OS) results from the final analysis of the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line...
Themefolio
Profiler
Peergroup
© PR Newswire
12.09.2024
MRK
LISTED
NYSE
Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prio
News Preview
KIRKLAND, QC, Sept. 12, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MS...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2024
MRK
LISTED
NYSE
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the Bank of America 2024 Global Healthcare Conference on Wednesday, Sept. 18, 2024, at 6:40 a.m. EDT / 11:40 a.m. BST.
Investors, analysts, members...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2024
MRK
LISTED
NYSE
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in Japanese males ages 16 to 26 years. The trial met its p...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
MRK
LISTED
NYSE
Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
News Preview
Approved indications include the treatment of adult patients with von Hippel-Lindau (VHL) disease for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery
KIRKLAND, QC, Sept. 5, 2024 /CNW/ - Merck (NYSE: MRK...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
MRK
LISTED
NYSE
WINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
News Preview
KIRKLAND, QC, Sept. 4, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that WINREVAIR® (sotatercept) is now authorized for use in Canada in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functi...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2024
MRK
LISTED
NYSE
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candidates in more than 20 types of cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from Sept. 13-17. Study findings from the Phase 3 KEY...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2024
MRK
LISTED
NYSE
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway, N.J., USA, today announced the initiation of the Phase 2b/3 BRUNELLO trial evaluating Restoret™ (MK-3000, formerly EYE103) for the treatment of diabetic macular edema (DME).
MK-3000 is an investigationa...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
MRK
LISTED
NYSE
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the first-line treatment of unresectable or metastatic urothelial carcino...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
MRK
LISTED
NYSE
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
MRK
LISTED
NYSE
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with stereotactic body radiotherapy (SBRT) for the treatment of pati...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
MRK
LISTED
NYSE
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of Shorespan-007, a pivotal Phase 3 clinical trial evaluating bomedemstat, an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, for the treatment of patients with essential thrombocythemia (ET) who have previously...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2024
MRK
LISTED
NYSE
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with World Health Organization (WHO) Functional Class (FC) II to III,...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
MRK
LISTED
NYSE
Health Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination with enfortumab vedotin
News Preview
Approval is based on the Phase 3 KEYNOTE-A39 Trial
KIRKLAND, QC, Aug. 22, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug conjugate, for the treatme...
Themefolio
Profiler
Peergroup
© BusinessWire
09.08.2024
MRK
LISTED
NYSE
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Curon Biopharmaceutical (Curon), a privately held biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire CN201, a novel investigational clinical-stage bispecific ant...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
